# High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT03263442** · PHASE2 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 66 (actual)

## Conditions studied

- Hematopoietic Stem Cell Transplantation
- Delirium
- Thiamine Deficiency

## Interventions

- **DRUG:** Thiamine
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT03263442
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-16
- **Primary completion:** 2020-03-02
- **Final completion:** 2020-08-10
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2021-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03263442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03263442, "High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03263442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*